Wow Scott. First off, absolutely none of your post is fact. In fact it's libel fiction. Prurisol very well could go past September 30th. Leo cutting the Aspire deal was nuts imo, but if he thinks the company will meet the deadlines, fine by me. Play IPIX accordingly. I see anticipation buying on many bios that are pending data. The surge itself can be very rewarding. Deciding to hold through results is the question. I'll be holding plenty for the long haul.
imo.
$IPIX to the bank.
In Reply to 'scottsmith' on 'Innovation Pharmaceuticals Inc. (IPIX)'
Message in reply to:
My post is a fact, I'm afraid.
You ask, "Milestones to which you're referring would be related to which development and which indication?"
Let's start here: if ipix doesn't meet any of the milestones by the September 30 date, that means Prurisol has failed. If Prurisol has failed, that means that IPIX is left with only Brilacidin. This is true because, a) Prurisol will have just failed and b) Kevetrin failed the K-OC trial (realistic point of view) (the shiny view of K would be that they simply don't have the money to proceed).
Let's continue here: if IPIX can't land a deal for OM of at least 10 million upfront, then we know that indication has no value to any other pharmas. We already know that absssi has no value to other pharamas or else Leo would have sold it or partnered it years ago instead of mothballing it.